H1 2023 Financial Highlights

Growth platforms: consistent strong performance Г Dysport® Clostridium botulinum Type A Toxin +31.7% Г CABOMETYX® (cabozantinib) tablets +26.3% Г Decapeptyl triptorelin +6.0% onivyde® (irinotecan liposome injection) +19.3% Further aesthetics-market growth, accompanied by favorable baseline effect Continued strong double- digit therapeutics growth across regions Strong volume uptakes across most geographies Momentum in first & second-line renal cell carcinoma China sales recovery post-COVID in Q2 Growth in Europe offset by adverse pricing Growth in the U.S. driven by market-share gains 1L PDAC pre-launch activities IPSEN Innovation for patient care All growth rates are at constant exchange rates. 1. North America only; excludes sales to ex-U.S. partner. Growth platforms: Dysport, Decapeptyl, Cabometyx and Onivyde; 1L: first line; PDAC: pancreatic ductal adenocarcinoma. 8

View entire presentation